NCT01414712终止不适用
Circulating Tumor Cells in Patients Undergoing Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- To review the level of changes in circulating tumor cells with radiation.
研究概览
简要总结
The purpose of this study is to determine if a non-invasive cancer treatment, high-dose stereotactic body radiotherapy (SBRT), is associated with changes in circulating tumor cells counts in patients with low- and intermediate-risk prostate cancer.
详细描述
SBRT (stereotactic body radiotherapy) may decrease or actually increase CTC levels in patients with cancer, and knowledge about the effects of different therapies, including SBRT, on CTC levels will be of general interest to the oncology community. Patients will undergo blood draws at defined times as indicated below.
- Prior to CT-simulation, but more than 2 days after digital rectal examination
- Within 24 hours following CT simulation (an endorectal balloon is used at the time of simulation)
- Within 24 hours following the first treatment
- Within 24 hours following the third treatment
- Within 1 week following the fifth treatment
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Men who satisfy all of the following conditions will be eligible for this study:
- •Willing and capable to provide informed consent
- •Signed study specific informed consent form.
- •PSA ≤ 20 prior to hormone therapy (if given) for patients with Gleason 2-
- •For those with Gleason score of
- •PSA should be less than or equal to 15 ng/ml prior to hormonal therapy (if given). Thus, risk of pelvic lymph node involvement according to Roach formula would be under 20%.
- •Gleason score ≤ 7
- •Appropriate staging studies identifying as AJCC stage T1a, T1b, T1c, T2a, or T2b
- •No direct evidence of regional or distant metastases after appropriate staging studies
- •Histologic confirmation of cancer by biopsy
- •Adenocarcinoma of the prostate
- •Zubrod Performance Status 0-2
- •Up to 9 months of previous hormonal therapy is allowed (but not required)
- •AUA score must be ≤ 15 (alpha blockers allowed)
- •CT or Ultrasound-based volume estimation of prostate gland ≤ 60 grams
- •Agreement to use effective contraceptive methods such as condom/diaphragm and spermicidal foam, intrauterine device, or prescription birth control pills.
排除标准
- •Women are not eligible for this study. Men with one or more of the following conditions also are ineligible for this study:
- •Positive lymph nodes or metastatic disease from prostate cancer
- •Prior invasive malignancy unless disease free for a minimum of 3 years (carcinoma in situ of the breast, oral cavity, or cervix, or non-melanomatous skin cancer are all permissible)
- •T2c, T3, or T4 tumors
- •Previous pelvic radiotherapy
- •Previous surgery or chemotherapy for prostate cancer
- •Previous transuretheral resection of the prostate (TURP) or cryotherapy to the prostate
- •Previous hormonal therapy given for more than 9 months prior to therapy
- •Concomitant antineoplastic therapy (including surgery, cryotherapy, conventionally fractionated radiotherapy, and chemotherapy) while on this protocol.
- •History of Crohn's Disease or Ulcerative Colitis.
- •Previous significant obstructive symptoms; AUA score must be ≤ 15 (alpha blockers allowed)
- •Significant psychiatric illness
- •Men of reproductive potential may not participate unless they agree to use an effective contraceptive method.
- •Ultrasound or CT estimate of prostate volume > 60 grams
结局指标
主要结局
To review the level of changes in circulating tumor cells with radiation.
时间窗: 2 weeks
The investigator will review the coutns of circulating tumor cells (CTC). If there are significant changes in CTC levels with radiation, future studies will determine the prognostic significance of this information.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
The changes of circulating tumor cells by stereotactic radiotherapy for huge tumor due to telomescamalignancyJPRN-UMIN000013500Tokyo Radiation Oncology Clinic10
已完成
1 期
Evaluation of Stereotactic Radiosurgery For Liver MalignanciesAdenocarcinomaLiver CancerCholangiocarcinomaNCT00230347Stanford University20
已完成
不适用
Radiologically Guided Biopsies of mCRPCProstate CancerNCT02432001University of California, San Francisco256
已完成
不适用
The Effect of Treatment on Circulating Tumor Cells in Bladder Cancer Patients With Muscle-invasive or Advanced DiseaseBladder CancerNCT00829920University of Colorado, Denver44
招募中
不适用
Stereotactic Radiosurgery in Patients With Head and Neck Region TumoursHead and Neck CancerNCT06472570Maria Sklodowska-Curie National Research Institute of Oncology80